Pharmaceutical Business Review
Anonymous User | Login

Genzyme acquires rights to multiple sclerosis drug from Bayer

Published: 03-Apr-2009

Genzyme to acquire Seattle-area Leukine manufacturing facility

Genzyme, a biotechnology company, has entered into an agreement to acquire the worldwide rights to Campath from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis.

Bayer will continue to fund a portion of alemtuzumab's development in multiple sclerosis (MS) and will retain an option to co-promote the product in MS upon approval. In addition, Genzyme will assume sole responsibility for worldwide sales and marketing for Campath in B-cell chronic lymphocytic leukemia, where it is indicated for use as a single agent in first-line and previously-treated patients with this disease. Bayer will retain the right to develop and commercialize alemtuzumab in solid organ transplant indications.

The agreement further expands Genzyme's hematologic oncology commercial presence beyond Campath through the addition of Fludara and Leukine, and provides an opportunity to integrate members of Bayer's experienced commercial team for all three drugs into Genzyme's global operations.

Genzyme will acquire a new, Seattle-area Leukine manufacturing facility for $75 to $100m and hire the plant's operating personnel following the FDA plant approval, which is expected in 2010. Bayer will receive payments based on revenues and potential milestone payments if cumulative revenue targets are achieved. There are no upfront payments for the rights of these three drugs.

Genzyme is now conducting two Phase III studies of alemtuzumab in MS. The first trial, for which enrollment is complete, treats early, active relapsing-remitting patients who have received no prior therapy.

The second study, which is expected to complete enrollment before the end of 2009, is studying relapsing-remitting patients who had active disease while on other MS therapies. Data from the trials are expected to be available in 2011, and approval is anticipated in 2012.

Henri Termeer, chairman and CEO of Genzyme, said: Alemtuzumab is a potentially transformative therapy for the treatment of multiple sclerosis, and an important part of our future. This strategic transaction clarifies the responsibilities of each company and gives Genzyme control over the execution of this program. We will continue to collaborate with Bayer in a more streamlined and focused way.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

eResearch Technology

Provider of Technology and Services ...

ETS Nederland BV

(Experimental Toxicology Services) ...

ProtNeteomix

Developing Applications for Drug Discovery & Development and Diagnostics ...

ADAPT Localization

The Translation and Localization Specialists ...

Centre for Human Drug Research

Question-Based Drug Development ...

TNO

Pharma Services: From Discovery to the Clinic ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model

Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...

USB HotStart-IT for Real Time PCR

USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Enabling Drug Delivery Deal Making

Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...

Automating Training Control Processes to Comply with FDA Requirements

Well-managed training programs minimize the risk of non-compliance and improve product qua ...

TNO Pharma Services: From Discovery to the Clinic

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

No items to display

Suppliers Product News

ERT Launches New Online Gateway to Improve Cardiac Safety in Clinical Trials

ERT, a leading provider of centralized ECG, ePRO, eClinical technology and other services to the biopharmaceutical, medical device and related industries, announced today the launch of a unique online web interface – My Study Portal.

ERT Officials Ring the NASDAQ Closing Bell

ERT (NASDAQ: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the biopharmaceutical, medical device and related industries, closed the stock market on 18 June by ringing the famous NASDAQ bell.

ERT Relocates Customer Care Team to Provide Stronger Client Support

ERT a leading provider of centralized ECG, ePRO, eClinical technology and other services to the biopharmaceutical, medical device and related industries, is to move its dedicated customer care team to its new state-of-the-art headquarters and logistics operations in Philadelphia.

Bridging Studies

A longstanding relationship between J-CLIPNET and CHDR was formalised by signing a Memorandum of Understanding on Nov 16 2009.

Amarna Therapeutics B.V. and TNO Announce SVac Research and Development Partnership

Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna's viral gene delivery platform SVac.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address